| Title |
Role of Aspirin in Cancer Prevention
|
|---|---|
| Published in |
Current Oncology Reports, October 2013
|
| DOI | 10.1007/s11912-013-0351-3 |
| Pubmed ID | |
| Authors |
Mangesh A. Thorat, Jack Cuzick |
| Abstract |
Since its first synthesis in 1897, several medicinal roles and mechanisms of action of aspirin have become apparent; the latest among these being its role in cancer prevention and treatment. A large body of evidence supports aspirin's effect in reducing cancer incidence and cancer mortality, but duration of use needs to be at least 5 years. The beneficial effects are particularly large for colorectal, oesophageal and gastric cancers, with apparently smaller reductions for breast, prostate and lung cancer. The major harm is gastrointestinal bleeding, but serious sequelae are minimal at ages <70 years. It is very likely that use of prophylactic aspirin in the general population aged 50-70+ years will result in net overall benefit. Outstanding issues are: whether standard dose (~300 mg/day) can lead to greater net benefits than low dose (75-100 mg/day), the optimum duration of use, and appropriate ages for use in average-risk individuals. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 140 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | <1% |
| Unknown | 139 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 25 | 18% |
| Student > Master | 23 | 16% |
| Researcher | 14 | 10% |
| Student > Ph. D. Student | 10 | 7% |
| Other | 7 | 5% |
| Other | 26 | 19% |
| Unknown | 35 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 38 | 27% |
| Biochemistry, Genetics and Molecular Biology | 21 | 15% |
| Agricultural and Biological Sciences | 11 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 5% |
| Chemistry | 7 | 5% |
| Other | 16 | 11% |
| Unknown | 40 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 September 2023.
All research outputs
#2,587,200
of 22,743,667 outputs
Outputs from Current Oncology Reports
#73
of 874 outputs
Outputs of similar age
#24,953
of 210,325 outputs
Outputs of similar age from Current Oncology Reports
#1
of 4 outputs
Altmetric has tracked 22,743,667 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 874 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.8. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 210,325 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them